The regenerative therapy developer is based on research at University of Torino and has raised capital from returning backer V-Bio Ventures.
AgomAb Therapeutics, a US-based regenerative therapy developer spun out of University of Torino, has completed a $74m series B round backed by V-Bio Ventures, the venture firm aligned with VIB.
Hedge fund manager Redmile Group led the round, which also featured Boehringer Ingelheim Venture Fund, the corporate venturing arm of pharmaceutical firm Boehringer Ingelheim.
Cormorant Asset Management, Advent France Biotechnology, Andera Partners, Omnes Capital and Pontifax filled out the round.
AgomAb is developing monoclonal antibody drugs intended…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
